- Home
- CODX vs NERV Comparison
CODX vs NERV Comparison
Compare CODX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- NERV
- Stock Information
- Founded
- CODX 2013
- NERV 2007
- Country
- CODX United States
- NERV United States
- Employees
- CODX N/A
- NERV N/A
- Industry
- CODX Medical/Dental Instruments
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- NERV Health Care
- Exchange
- CODX Nasdaq
- NERV Nasdaq
- Market Cap
- CODX 15.6M
- NERV 14.6M
- IPO Year
- CODX 2017
- NERV 2014
- Fundamental
- Price
- CODX $0.33
- NERV $4.07
- Analyst Decision
- CODX Buy
- NERV Hold
- Analyst Count
- CODX 2
- NERV 1
- Target Price
- CODX $2.00
- NERV $4.00
- AVG Volume (30 Days)
- CODX 61.3M
- NERV 8.7M
- Earning Date
- CODX 11-13-2025
- NERV 11-05-2025
- Dividend Yield
- CODX N/A
- NERV N/A
- EPS Growth
- CODX N/A
- NERV N/A
- EPS
- CODX N/A
- NERV N/A
- Revenue
- CODX $507,892.00
- NERV N/A
- Revenue This Year
- CODX N/A
- NERV N/A
- Revenue Next Year
- CODX $31.58
- NERV N/A
- P/E Ratio
- CODX N/A
- NERV N/A
- Revenue Growth
- CODX N/A
- NERV N/A
- 52 Week Low
- CODX $0.23
- NERV $1.15
- 52 Week High
- CODX $1.55
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- CODX 44.98
- NERV 56.14
- Support Level
- CODX $0.38
- NERV $3.52
- Resistance Level
- CODX $0.40
- NERV $4.20
- Average True Range (ATR)
- CODX 0.07
- NERV 0.37
- MACD
- CODX -0.02
- NERV -0.08
- Stochastic Oscillator
- CODX 2.26
- NERV 44.62
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.